Security key
98937L105
Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO)
CUSIP: 98937L105
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 34,774,383
- Total 13F value
- $771,813,059
- Share change
- +717,476
- SEC-reported price per share
- $22.20
- Number of holders
- 78
- Value change
- +$23,276,708
- Number of buys
- 35
- Number of sells
- 28
- Shares outstanding
- 63,278,585
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
78
Top holders
10
ZBIO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Zenas BioPharma, Inc. SEC filings
Zenas BioPharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98937L105
Recent filing periods:
Ownership snapshot
Top reported holders of ZBIO - Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Novo Holdings A/S
Disclosed value leader
Enavate Sciences GP, LLC
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
3/4/5
Lead comparable stake: 4.7%
13D/G row: Novo Holdings A/S
Showing 1-6 of 15 holder rows.
Quick read
Novo Holdings A/S leads the comparable SEC ownership view at 4.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Novo Holdings A/S's linked filing trail.
Comparable ownership
Top 5
Novo Holdings A/S
4.7%
SR ONE CAPITAL MANAGEMENT, LP
7.8%
Enavate Sciences GP, LLC
5.9%
FMR LLC
5.3%
NEA Management Company, LLC
4.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Novo Holdings A/S |
13D/G
13F
Company
|
4.7%
|
$44,400,000
2,000,000 shares
|
-$4,772,267 | 30 Sep 2025 |
| SR ONE CAPITAL MANAGEMENT, LP |
13F
Company
|
7.8%
|
$47,592,813
4,911,539 shares
|
— | 30 Jun 2025 |
| Enavate Sciences GP, LLC |
3/4/5
13F
10%+ Owner · Company
|
5.9%
from 13F
|
$63,943,103
3,761,359 shares
|
— | 16 Sep 2024 |
| FMR LLC |
13F
Company
|
5.3%
|
$32,205,045
3,323,534 shares
|
— | 30 Jun 2025 |
| NEA Management Company, LLC |
13F
Company
|
4.3%
|
$26,489,737
2,733,719 shares
|
— | 30 Jun 2025 |
| Fairmount Funds Management LLC |
13F
Company
|
3%
|
$18,341,290
1,892,806 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
78
Shares
34,774,383
Rows available
78
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
72
Q3 2025 holders
78
Holder diff
6
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend